Pulmonary delivery of low-dose dexamethasone significantly reduces toxicity in acute lung injury therapy
文献类型：期刊论文
| 作者 | Nie, Qin1,5; Liu, Jiahe1,5; Cui, Ying1,5; Li, Feng1,4; Bello, Mubarak G.3; Wang, Jialong1,4; Zheng, Shiyu1; Shao, Shuang3; Wu, Li1; Wang, Caifen1,2,5 |
| 刊名 | INTERNATIONAL JOURNAL OF PHARMACEUTICS
 |
| 出版日期 | 2026-03-10 |
| 卷号 | 692页码:12 |
| 关键词 | Inhalable DEX dry powder Pulmonary delivery Low-dose Alleviate ALI Reduce toxicity |
| ISSN号 | 0378-5173 |
| DOI | 10.1016/j.ijpharm.2026.126627 |
| 通讯作者 | Wang, Caifen(wangcaifen@simm.ac.cn) ; Sun, Lixin(slx04@163.com) ; Zhang, Jiwen(jwzhang@simm.ac.cn) |
| 英文摘要 | Dexamethasone (DEX), a potent glucocorticoid with anti-inflammatory and immunosuppressive properties, exhibits dose-limiting systemic toxicity during long-term use. Inhalation therapy enables targeted pulmonary delivery, enhancing therapeutic efficacy while minimizing systemic exposure compared to oral routes. This study designed a DEX dry powder inhaler (DPI) formulation exhibiting excellent aerodynamic performance with a good fine particle fraction (FPF = 49.01%), which achieved approximately 7.1-fold higher pulmonary exposure relative to intravenous injection at an equivalent dose. Additionally, a 10-fold dose reduction of DEX achieved equivalent efficacy to the i.v. DEX group and significantly alleviated acute lung injury (ALI). The elevation ratios of lung coefficient in the intragastric administration of DEX raw material solution (i.g. DEX) group at 7, 14, and 28 days were approximately 4.0-, 2.1-, and 5.8-fold higher than those of in the inhalation of low-dose DEX DPI formulation (inhal. L-DEX) group in tolerability evaluation, indicating the less severe pulmonary edema in the inhalation group. Notably, a 10-fold lower DEX dose administered via inhalation reduced significantly systemic and pulmonary toxicity by organ and blood indicators at 7, 14 and 28 days, compared to high-dose intragastric administration (p < 0.01). Overall, this optimized pulmonary DEX delivery strategy demonstrated significant potential for clinical translation, offering enhanced lung targeting, efficacy at reduced doses, and a favorable safety profile. |
| WOS关键词 | DRUG-DELIVERY ; MECHANISMS ; PHARMACOKINETICS ; EXPRESSION ; ENZYMES |
| 资助项目 | Creation and Development |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001682427200001 |
| 出版者 | ELSEVIER |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/322830]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Wang, Caifen; Sun, Lixin; Zhang, Jiwen |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Delivery Syst, 501 Haike Rd, Shanghai 201203, Peoples R China 2.Natl Inst Food & Drug Control, China NMPA Key Lab Qual Res & Evaluat Pharmaceut E, 2 Tiantan Xili, Beijing 100050, Peoples R China 3.Jiangxi Univ Chinese Med, Key Lab Modern Preparat TCM, Minist Educ, Nanchang 330004, Peoples R China 4.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 5.Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut Anal, 103 Wenhua Rd, Shenyang 110016, Peoples R China |
| 推荐引用方式 GB/T 7714 | Nie, Qin,Liu, Jiahe,Cui, Ying,et al. Pulmonary delivery of low-dose dexamethasone significantly reduces toxicity in acute lung injury therapy[J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS,2026,692:12. |
| APA | Nie, Qin.,Liu, Jiahe.,Cui, Ying.,Li, Feng.,Bello, Mubarak G..,...&Zhang, Jiwen.(2026).Pulmonary delivery of low-dose dexamethasone significantly reduces toxicity in acute lung injury therapy.INTERNATIONAL JOURNAL OF PHARMACEUTICS,692,12. |
| MLA | Nie, Qin,et al."Pulmonary delivery of low-dose dexamethasone significantly reduces toxicity in acute lung injury therapy".INTERNATIONAL JOURNAL OF PHARMACEUTICS 692(2026):12. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。